Consumers of BounceBack™ capsules know they work—and now a recent

double-blind, placebo-controlled, crossover pilot study confirms it.

As presented at the 2008 International Society of Sports Nutrition Conference and Expo, June 9 -10,2008, Las Vegas, NV, USA

Effect of a combination dietary supplement product

(BounceBack™) on the signs and symptoms of delayed onset
muscle soreness after eccentric exercise: a randomized,
double-blind, placebo-controlled, crossover pilot study
Jay Udani , Betsy Singh , Vijay Singh , Elizabeth Sandoval
12 1 1 1
1
Medicus Research LLC, 18250 Roscoe Blvd. Suite 240, Northridge, CA 91325
2
UCLA/Geffen School of Medicine, Department of Medicine, Los Angeles, CA

BACKGROUND
Delayed onset muscle soreness (DOMS) is muscle pain and discomfort experienced approximately one to three
days after exercise and is believed to be a result of microscopic muscle fiber tears. The MeanBounceBack™ product is
VAS Scores Immediately Post-exercise
200
Myogl

a combination of several dietary supplement ingredients which have individually been shown to improve the 1.2

inflammation and pain associated with DOMS (digestive enzymes, Bromelain, Curcumin, Vitamin C) in com-
1 1.0938 150

Myoglobin and CPK Levels With BounceBack™* 0.8

bination with an Avocado Soy extract and Resveratrol.* The purpose

Mean VAS Scores Immediately Post-exercise of the study was to evaluate the ability of
200
0.6
0.8229 100

the BounceBack™ product to reduce the signs and symptoms of DOMS and increase the rate of muscle recovery
1.2
60
0.4
1 1.0938 150

following eccentric exercise. 0.3571 50

0.2 0.3095
0.8
100 40
0.8229
0
0.6 Least Severe Muscle Pain In Past Week, Interference of Pain with Activities,
30
p=0.002 p=0.047 Baseli
60 BounceBack™ (Pre-Exe
0.4 Placebo
0.3571 50 *Between group diff
0.2 0.3095
40

PURPOSE AND HYPOTHESIS

0
Least Severe Muscle Pain In Past Week, Interference of Pain with Activities,
30
p=0.002 p=0.047 Baseline Baseline Baseline Visit 2 Visit 3 Visit 4
BounceBack™ Mean
(Pre-Exercise) VAS Pain
(Post-Exercise) Scores(24
(6 hrs) athrs)6 Hours After (72
(48 hrs) hrs)
Placebo Eccentric Exercise
CPK BounceBack™ Myoglobin BounceBack™
1.2
*Between group differences were not significant. CPK placebo Myoglobin placebo 16

14
1 1.1146

This protocol was designed to provide a structured study in which to 0.8

12

10

evaluate the ability of BounceBack™ to reduce the signs andExercise

symptoms
Mean VAS Pain Scores at 6 Hours After Total VAS Pain Score at 48 Hours After
Eccentric 0.6 Eccentric Exercise
0.6905 8
1.2 16

of DOMS and increase the rate of muscle recovery following eccentric

1 1.1146
0.4
14
13.9821
6

exercise. Additionally, the total energy expenditure and measured ac-

12
0.2
0.8 2
10

tive energy expenditure were tracked during the eccentric exercise and
0 0
0.6 0.6905 8 Current Severity of Muscle Pain, BounceBack™
p=0.039
Placebo
on the days preceding the exercise.
6 7.2857
0.4
4
0.2
2

0 0
Current Severity of Muscle Pain, Mean Total VAS Pain Score, p=0.050
Tot
BounceBack™ BounceBack™
p=0.039
Placebo Placebo 800

700

600

MATERIALS AND METHODS

500
Total Energy Expenditure and Measured Active
Energy Expenditure With BounceBack™
METs

400
800
300
700
719.6
200
600

A randomized, double-blind, placebo-controlled, crossover study was 500

100

0
METs

performed with 10 healthy, untrained subjects between the ages of 18

400 459.5

300

and 45. Subjects were screened for eligibility and then randomized to 200
210.86

receive the active or placebo product for 33 days. Subjects wore the
100
88.31
0
Total Energy Expenditure Measured Active Energy

BodyMedia Armband Monitoring System during days 28-30 to track (p=0.009) Expenditure (p=0.0001)
BounceBack™

their pre-exercise activity level. Subjects returned on day 30 to undergo

Placebo

a standardized eccentric exercise protocol (isokinetic quadriceps squat

contractions). Subjects underwent pain and tenderness (algometer)
Mean VAS Scores Immediately Post-exercise
Myoglobin and CPK Levels With BounceBack™*
200
evaluations and blood draws just prior to exercise, immediately post-
1.2

exercise, and again at 6, 24, 48, and 72 hours post-exercise. Subjects

1 1.0938 150

underwent a two week washout, and were then crossed over to the oth-
0.8
0.8229 100

0.6

er arm of the study. Mean differences between groups were assessed in-
0.4
60
Myoglobin and CPK Levels With BounceBack™*
ferentially at each data collection time-point. Mean VAS Scores Immediately Post-exercise
0.3571 50
0.2 0.3095 200
1.2 40
0
Least Severe Muscle Pain In Past Week,
1.0938 Interference of Pain with Activities, 150
1 30
p=0.002 p=0.047 Baseline Baseline Baseline Visit 2 Visit 3 Visit 4
BounceBack™ (Pre-Exercise) (Post-Exercise) (6 hrs) (24 hrs) (48 hrs) (72 hrs)
0.8 Placebo CPK BounceBack™ Myoglobin BounceBack™
0.8229 100 CPK placebo Myoglobin placebo
*Between group differences were not significant.

0.6
60
0.4

0.3571 50
0.2 Mean VAS Pain Scores at0.3095
6 Hours After Total VAS Pain Score at 48 Hours After
Eccentric Exercise 40
Eccentric Exercise
1.2 16
0
Least Severe Muscle Pain In Past Week, Interference of Pain with Activities,
30 14

RESULTS
1 p=0.002 1.1146p=0.047 Baseline Baseline Baseline Visit 2 Visit 3 Visit 4
BounceBack™ (Pre-Exercise) (Post-Exercise) (6 hrs) (24 hrs)
13.9821 (48 hrs) (72 hrs)
12
Placebo CPK BounceBack™ Myoglobin BounceBack™
0.8 CPK placebo Myoglobin placebo
*Between10
group differences were not significant.

0.6 0.6905 8

6 7.2857

Statistically significant differences were observed in favor ofEccentric

theScores
BounceBack™
0.4
Mean VAS Pain at 6 Hours After 4 Total VAS Pain Score at 48 Hours After
0.2 Exercise Eccentric Exercise
product for pain, tenderness, and amount of energy expended. At 6
1.2 2
16
0 0
14

hours, the current severity of muscle pain VAS assessments was lower
1 1.1146
Current Severity of Muscle Pain, BounceBack™ Mean Total VAS Pain Score, p=0.050
p=0.039 13.9821 BounceBack™
Placebo 12
Placebo
0.8

(0.6905 v 1.1146, p=0.039), and at 48 hours, the total VAS pain assess-
10

0.6 0.6905 8

ment was significantly lower (7.2857 v 13.9821, p=0.050) in the active

0.4
6 7.2857
Total Energy Expenditure and Measured Active
Energy Expenditure With BounceBack™
group. At 24 hours, the tenderness after algometry was significantly
4
0.2 800
2

lower (1.7245 v 2.3750, p=0.042) in the active group.*

700
0 0 719.6
Current Severity of Muscle Pain, BounceBack™ Mean Total VAS Pain Score, p=0.050
600 BounceBack™
p=0.039
Placebo Placebo
500

Based on the BodyMedia armband data, the active group recorded

METs

400 459.5

significantly greater Total Energy Expenditure (710.60 v 459.50 METs,

300

Total
200 Energy Expenditure and Measured Active
Energy Expenditure With210.86
BounceBack™
p=0.009) and Measured Active Energy Expenditure (210.86 v 88.31 800
100

7000
88.31

METs, p=0.000). Serological markers of muscle damage (CPK and 600

719.6 Expenditure
Total Energy
(p=0.009)
Measured Active Energy
Expenditure (p=0.0001)
BounceBack™

Myoglobin) were lower in the active group throughout the entire post- 500
Placebo
METs

400 459.5

exercise period, but this difference did not reach statistical significance.* 300

200
210.86
100
88.31
0
Total Energy Expenditure Measured Active Energy
(p=0.009) Expenditure (p=0.0001)

CONCLUSIONS
BounceBack™
Placebo

In this small pilot study, the BounceBack™ product resulted in a significant reduction in standardized measures
of pain and tenderness post-eccentric exercise, even after engaging in significantly more activity in the two day
period prior to the exercise protocol. The differences in the serological markers of DOMS, while not statistically
significant, appear to support the clinical findings.* Further study with a larger sample size is warranted based
on the current results.

The authors would like to thank Mannatech Incorporated for funding this research.

BIBLIOGRAPHY
Volek JS, et al. Am J Physiolo Endocrinol Metab 2002; 282: E474-E482
Beck TW, et al. J Strength Cond Res. 2007; 21(3): 661-667
Davis JM, et al. Am J Physiol Regul Integr Comp Physiol. 2007 Jun; 292
(6):R2168-73
Connolly DA et al. J Sports Med Phys Fitness. 2006 Sep; 46(3): 462-7
Kingsley MI, et al. Med Sci Sports Exerc. 2006 Sep; 38 (9):1617-25
Braun WA, et al. J Sports Med Phys Fitness. 2005 Dec; 45 (4):553-60
Lenn J, et al. Med Sci Spots Exerc. 2002 Oct; 34 (10):1605-13

* These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure or prevent any disease.
Enriching Quality of Life SM